- Home
- Equipment
- australasia
- bladder cancer patient
Refine by
Bladder Cancer Patient Equipment & Supplies In Australasia
5 equipment items found
Manufactured by:Nucleix Ltd. based inSan Diego, CALIFORNIA (USA)
Bladder cancer is the 5th most common cancer in the western world, and 70%-80% of the patients are diagnosed with non-muscle invasive disease. There are estimated 400,000 to 800,000 active bladder cancer patients in the United States, as well as 1 to 2 million in Europe, who ...
Manufactured by:Cysview, Trademark of Photocure based inPrinceton, NEW JERSEY (USA)
Historically, bladder cancer patients are at high risk for disease recurrence and progression,1 which could be due in part to missed tumors and incomplete surgeries because not all cancerous tissue is easy to see under white light. Moving forward, with the availability of Blue Light Cystoscopy with Cysview, that trend may ...
by:Theralase Technologies Inc. based inToronto, ONTARIO (CANADA)
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients globally. Theralase is dedicated to safely and effectively destroying ...
Manufactured by:Pacific Edge Ltd based inDunedin,, NEW ZEALAND
Cxbladder is a non-invasive genomic urine test that quickly and accurately detects or rules out bladder cancer. The tests works at a molecular level, measuring five biomarker genes to detect the presence or absence of bladder cancer1, and comes as a suite of three product variations, each optimised for a different point in the ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1/2 at low nanomolar ...